NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S. NEWSWIRES
TORONTO, ONTARIO – (December 16, 2016) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce the successful completion of the first tranche of a private placement of units consisting of brokered and non-brokered components, raising gross proceeds of $2,426,745 (the “Offering”). Net proceeds from the Offering will be used for clinical development and for general corporate purposes.
Under the terms of the Offering, 16,178,299 units (the “Units”) were sold at a price of $0.15 per Unit, with each Unit comprising of one Common Share of the Corporation and one-half of one Common Share purchase warrant (“Warrant”). Each whole Warrant entitles the holder to purchase an additional Common Share (“Warrant Share”) at a price of $0.22 per Warrant Share until December 15, 2018. Dominick Inc. acted as agent on the brokered private placement component.
In connection with the Offering, Dominick (including selling group members) received a cash commission equal to $162,054 and 1,138,088 broker warrants (the “Broker Warrants”). Each Broker Warrant will entitle the holder to purchase one Common Share at a price of $0.15 per share until June 15, 2018.
The total non-brokered portion of the Offering comprised of 2,011,667 units for gross proceeds of $301,750. Insiders of the Corporation and their affiliates subscribed for 1,300,000 Units under the Offering for aggregate cash consideration of $195,000.
The securities issued are subject to a four-month statutory hold period and a TSX Venture Exchange hold period, each expiring on April 16, 2017. Antibe may complete a further closing of the Offering not to exceed a maximum offering amount of $3,000,000, subject to the right of Dominick to further increase the size of the Offering by 15% to bring total proceeds to $3,450,000, on or before December 31, 2016. The Offering is subject to TSX Venture Exchange final approval.
The participation of insiders in the Offering constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) and the policies of the TSX Venture Exchange. The Company is relying on the exemptions from the formal valuation and minority approval requirements contained in sections 5.5(b) and 5.7(a) of MI 61-101.
This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States or any other jurisdiction in which such an offer or solicitation is unlawful. The securities have not been and will not be registered under the United Sates Securities Act of 1933, as amended, (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state laws. No public offering of securities will be made in the United States.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of further closings of the Offering, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, failure to obtain TSX Venture Exchange approval for the transactions described herein, its ability to conclude partnering or other relationships with pharmaceutical companies, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Antibe Therapeutics Inc.
Chief Executive Officer
Tel: +1 416-473-4095
Read all news